Significance of simultaneous determination of serum human chorionic gonadotropin (hCG) and hCG-beta in testicular tumor patients

2000 ◽  
Vol 7 (6) ◽  
pp. 218-223 ◽  
Author(s):  
Senji Hoshi ◽  
Ken-Ichi Suzuki ◽  
Shigeto Ishidoya ◽  
Chikara Ohyama ◽  
Makoto Sato ◽  
...  
2004 ◽  
Vol 50 (7) ◽  
pp. 1214-1221 ◽  
Author(s):  
Sichun Zhang ◽  
Chao Zhang ◽  
Zhi Xing ◽  
Xinrong Zhang

Abstract Background: An inductively coupled plasma mass spectrometry (ICP-MS)-based immunoassay has been proposed independently by Baranov et al. (Anal Chem 2002;74:1629–36) and our group, but the applicability of this method for multianalyte analysis in clinical samples has not been fully illustrated. We developed a dual-label immunoassay method for the simultaneous determination of α-fetoprotein (AFP) and free β-human chorionic gonadotropin (hCGβ) in human serum. Methods: Monoclonal antibodies immobilized on microtiter plates captured AFP and hCGβ, which were detected by use of Eu3+-labeled anti-AFP and Sm3+-labeled anti-hCGβ monoclonal antibodies. Eu3+ and Sm3+ were dissociated from the immunocomplex with HNO3 solution (10 mL/L) and delivered by peristaltic pump to the ICP mass spectrometer. Results: The measurable ranges of AFP and hCGβ were 4.6–500 and 5.0–170 μg/L, respectively, with detection limits of 1.2 and 1.7 μg/L (3 SD above mean of zero calibrator), respectively. The intraassay imprecision (CV) for AFP was 8.3%, 4.0%, and 2.7% at 16.3, 86, and 354 μg/L, respectively, and the interassay CV was 10%, 5.7%, and 3.5%. For hCGβ, the intraassay CV was 5.4%, 6.4%, and 3.1%, respectively, at 10.5, 45.2, and 105 μg/L, and the interassay CV was 7.2%, 8.0%, and 3.7%. Comparison with IRMAs for AFP and hCGβ yielded correlation coefficients (r2) of 0.97 and 0.95. Conclusions: Two proteins can be measured simultaneously by immunoassays using two rare earth elemental tags (Eu3+ and Sm3+) and ICP-MS detection. The multielement capability and the multiple potential elemental labels make ICP-MS attractive for multianalyte immunoassays. Implementation of ICP-MS-linked immunoassays may be relatively straightforward because the labeling and immunoreaction procedures have been well developed for clinical time-resolved immunofluorometric assays.


1993 ◽  
Vol 39 (2) ◽  
pp. 229-233 ◽  
Author(s):  
S Madersbacher ◽  
S Schwarz ◽  
K Mann ◽  
R Klieber ◽  
G Wick ◽  
...  

Abstract To evaluate in vivo the proposed intrinsic thyroid-stimulating hormone (TSH) activity (TSA) of human chorionic gonadotropin (hCG), we monitored over 0.5-1 years the thyroid status of eight patients with hCG-producing non-seminomatous testicular cancer. The patients' sera were analyzed for concentrations of hCG, free thyroxine (fT4), hTSH, and thyroxine-binding globulin (TBG). All patients had excessively high concentrations of hCG (1 x 10(5)-5 x 10(8) ng/L, mean: 1 x 10(7) ng/L) before polychemotherapy, which decreased under successful therapy to physiological values (< 240 ng/L). Although the serum concentrations of hCG varied by more than six orders of magnitude, we saw no changes and no correlation (P > 0.05) between the concentrations of hCG and the concentrations of fT4 and hTSH. Not even when hCG concentrations were greatest (> 5 x 10(7) ng/L) were any signs of hyperthyroidism observed: fT4 (3.5-13 ng/L) and hTSH (9-700 ng/L) were in the physiological range in all patients and remained so during chemotherapy. The results of this longitudinal study were confirmed in analyzing the data for all eight patients (total: 82 samples) cross-sectionally. Again, we found no correlation (P > 0.05) between the concentrations of hCG and fT4 or hCG and hTSH. We conclude that even excessive amounts of testicular tumor-derived hCG do not display any TSH-like activity in vivo.


2008 ◽  
Vol 54 (11) ◽  
pp. 1840-1843 ◽  
Author(s):  
Anna Lempiäinen ◽  
Ulf-Håkan Stenman ◽  
Carl Blomqvist ◽  
Kristina Hotakainen

Abstract Background: We studied whether measurement of the free β subunit of human chorionic gonadotropin (hCGβ) in serum offers additional diagnostic information compared to determination of intact hCG alone in testicular cancer. Methods: We determined hCG and hCGβ with ultrasensitive assays in 94 serum samples obtained preoperatively, 22 samples obtained during relapse, and 3687 samples obtained during routine follow-up of 351 patients with testicular tumors. Results: In preoperative samples, isolated increases of hCGβ were seen in 40% of the samples from seminoma patients (n = 42) and in 8% of those from patients with nonseminomatous testicular cancer (NSGCT) (n = 51). Both markers were increased in 12% of the seminoma and 71% of the NSGCT patients and were within reference intervals in 43% of the seminoma and 20% of the NSGCT patients. Specific determination of hCGβ increased the frequency of marker-positive seminomas from 17% to 57% and of marker-positive relapses from 32% to 59% (n = 22). Theoretically, about 40% of marker-positive seminomas and relapses would have been missed with an assay measuring hCG and hCGβ together. Preoperative hCG and hCGβ concentrations correlated with stage, tumor histology, and disease-related mortality. Additionally, hCGβ correlated with tumor size. Conclusions: hCGβ is a diagnostically sensitive marker for testicular cancer. In patients with seminomatous testicular cancer, hCGβ is superior to hCG, and in some NSGCT patients it provides additional information.


Sign in / Sign up

Export Citation Format

Share Document